Effect of subthalamic deep brain stimulation on the function of the urinary bladder

Seif, C.; Herzog, Jan; Horst, Christof van der; Schrader, B.; Volkmann, Jens; Deuschl, Günther; Juenemann, Klaus‐Peter; Braun, P.

doi:10.1002/ana.10806

Cited by 132 publications

(85 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The activation of the cerebellum and supplementary motor area seen was in a similar distribution to that shown by fMRI in control subjects who performed pelvic £oor contraction with full bladders and inhibited voiding [Zhang et al, 2005]. Studies of bladder function following implantation of a deep brain stimulator for treatment of advanced movement disorders have show a reduction in DO and increased capacity [Finazzi-Agro et al, 2003;Seif et al, 2004] although the e¡ect of this intervention on urinary symptoms appears to be more complex.…”

Section: The Onset Of Bladder Symptoms In the Progression Of Pdsupporting

confidence: 54%

Update on the neurology of Parkinson's disease

Fowler

2006

Neurourology and Urodynamics

View full text Add to dashboard Cite

The di¡erential diagnosis of a patient with apparent Parkinson's Disease (PD) and bladder symptoms is considered and the bladder dysfunction of Multiple System Atrophy (MSA) is reviewed. Recent insights into the progression of the neuropathology of PD have enabled thinking about the stage of the disease at which bladder dysfunction is likely to occur and the expected clinical context of the problem. Bladder symptoms of neurological origin are likely in a patient who has had treated motor symptoms for some years and in whom the ongoing neuropathology has progressed beyond involvement of the basal ganglia, so that symptoms due to cortical dysfunction as well as the adverse e¡ects of dopaminergic medication are also confounding factors. Bladder symptoms in a man with lesser neurological disability should be investigated to exclude underlying out£ow obstruction. Possible management options are considered. Neurourol. Urodynam. 26: 103^109, 2007.

show abstract

Section: The Onset Of Bladder Symptoms In the Progression Of Pdsupporting

confidence: 54%

Update on the neurology of Parkinson's disease

Fowler

2006

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

“…70 Some improvement in nonmotor symptoms has been reported, such as in constipation, 71 sleep, 71,72 sensory complaints, 72,73 and some bladder complaints, 74 as well as urodynamic parameters. 75 A randomized study has confirmed the superiority of STN DBS to medical management at 6 months followup. 56 Some studies have shown that STN DBS is a costeffective treatment of advanced Parkinson's disease.…”

Section: Beneficial Effectmentioning

confidence: 94%

Deep Brain Stimulation for Parkinson’s Disease

2008

View full text Add to dashboard Cite

Summary:The surgical treatment of Parkinson's disease has been through a revival phase over the last 20 years with the development of deep brain stimulation (DBS). Thalamic DBS was developed first and has proven to be a very effective treatment for tremor. The limitation is the lack of effect on other symptoms. Other targets were therefore investigated, and the procedure was applied to the subthalamic nucleus (STN) and the internal globus pallidus (GPi). STN stimulation can improve a wide range of symptoms and is currently the preferred target for many patients. Nevertheless, the morbidity seems higher than with other targets, and the selection criteria have to be quite strict. When STN DBS is not advised, thalamic DBS remains an option for patients with severe tremor, and GPi stimulation for those with severe dyskinesias. DBS remains a symptomatic treatment for a limited number of patients; it does not seem to alter the disease progression, and many patients are not suitable. There is, therefore, the need for further research into other targets and other approaches.

show abstract

“…13 Two Class IV studies found that deep brain stimulation (DBS) of the subthalamic nucleus (STN) improved bladder capacity and volume. 14,15 Conclusions. Data for the treatment of urinary incontinence with apomorphine or DBS are insufficient.…”

Section: What Treatments Are Effective For Sexual Dysfunction In Pd?mentioning

confidence: 99%

Practice Parameter: Treatment of nonmotor symptoms of Parkinson disease [RETIRED]

et al. 2010

View full text Add to dashboard Cite

Objective: Nonmotor symptoms (sleep dysfunction, sensory symptoms, autonomic dysfunction, mood disorders, and cognitive abnormalities) in Parkinson disease (PD) are a major cause of morbidity, yet are often underrecognized. This evidence-based practice parameter evaluates treatment options for the nonmotor symptoms of PD. Articles pertaining to cognitive and mood dysfunction in PD, as well as treatment of sialorrhea with botulinum toxin, were previously reviewed as part of American Academy of Neurology practice parameters and were not included here. Methods:A literature search of MEDLINE, EMBASE, and Science Citation Index was performed to identify clinical trials in patients with nonmotor symptoms of PD published between 1966 and August 2008. Articles were classified according to a 4-tiered level of evidence scheme and recommendations were based on the level of evidence. Results and Recommendations:Sildenafil citrate (50 mg) may be considered to treat erectile dysfunction in patients with Parkinson disease (PD) (Level C). Macrogol (polyethylene glycol) may be considered to treat constipation in patients with PD (Level C). The use of levodopa/carbidopa probably decreases the frequency of spontaneous nighttime leg movements, and should be considered to treat periodic limb movements of sleep in patients with PD (Level B). There is insufficient evidence to support or refute specific treatments for urinary incontinence, orthostatic hypotension, and anxiety (Level U). Future research should include concerted and interdisciplinary efforts toward finding treatments for nonmotor symptoms of PD. Neurology The Quality Standards Subcommittee (QSS) of the American Academy of Neurology (AAN) develops scientifically sound, clinically relevant practice parameters to aid in the practice of neurology. This article evaluates treatment options for nonmotor symptoms of Parkinson disease (PD).While PD is considered a disorder characterized by motor symptoms, nonmotor symptoms are an integral part of this syndrome. These symptoms can be as troublesome as motor symptoms and impact activities of daily living, though they are often underrecognized by health care professionals.1,2 The nonmotor symptoms reviewed for this guideline were autonomic dysfunction (gastrointestinal disorders, orthostatic hypotension, sexual dysfunction, urinary incontinence), sleep disorders (restless legs syndrome, periodic limb movements of sleep, excessive daytime somnolence, insomnia, REM sleep behavior disorder), fatigue, and anxiety. Articles pertaining to cognitive and mood dysfunction in PD, as well as treatment of sialorrhea with botulinum toxin, were reviewed as part of previous AAN practice parameters 3,4 and were not included here.

show abstract

Effect of subthalamic deep brain stimulation on the function of the urinary bladder

Cited by 132 publications

References 15 publications

Update on the neurology of Parkinson's disease

Update on the neurology of Parkinson's disease

Deep Brain Stimulation for Parkinson’s Disease

Practice Parameter: Treatment of nonmotor symptoms of Parkinson disease [RETIRED]

Contact Info

Product

Resources

About